HBPCF (Helix BioPharma) Interest Expense: $-0.02 Mil (TTM As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Interest Expense?

Helix BioPharma HBPCF 28 Interest Expense is $-0.02 Mil as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Helix BioPharma's interest expense for the three months ended in Apr. 2026 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Helix BioPharma's Operating Income for the three months ended in Apr. 2026 was $ -0.50 Mil. Helix BioPharma's Interest Expense for the three months ended in Apr. 2026 was $ -0.01 Mil. Helix BioPharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Helix BioPharma  (OTCPK:HBPCF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Helix BioPharma's Interest Expense for the three months ended in Apr. 2026 was $-0.01 Mil. Its Operating Income for the three months ended in Apr. 2026 was $-0.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Apr. 2026 was $0.00 Mil.

Helix BioPharma's Interest Coverage for the quarter that ended in Apr. 2026 is calculated as

Helix BioPharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Helix BioPharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Interest Expense Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.00 -0.01 -0.01 -0.01
HBPCF
28GF Score
Helix BioPharma Corp HBPCF
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.02 Mil mean?
Helix BioPharma (HBPCF) has a Interest Expense of $-0.02 Mil as of Apr. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's Interest Expense too high?
Helix BioPharma's current Interest Expense is $-0.02 Mil. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Interest Expense compare to VRTX and REGN?
Helix BioPharma's Interest Expense of $-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current Interest Expense is $-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Interest Expense of $-0.02 Mil. The current Interest Expense is $-0.02 Mil. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Interest Expense is $-0.02 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price